Colorectal cancer is the second most common cause of cancer-related deaths in the U.S., killing approximately 53,000 people each year. Despite this, 50 million people eligible for screenings don’t do them, says Guardant Health co-CEO AmirAli Talasaz, and one study found 76% of deaths occurred in patients who hadn’t been screened. Guardant’s Shield test makes screening as routine as getting blood drawn—that’s all it entails. A much pleasanter option than colonoscopies and stool samples, the Shield test detects colon cancer tissue in blood samples using data analysis and AI. A March 2024 study in The New England Journal of Medicine put Shield’s detection sensitivity rate at 83%, and it was FDA approved for use in the U.S. in July.
More Must-Reads from TIME
- How the Electoral College Actually Works
- Your Vote Is Safe
- Mel Robbins Will Make You Do It
- Why Vinegar Is So Good for You
- The Surprising Health Benefits of Pain
- You Don’t Have to Dread the End of Daylight Saving
- The 20 Best Halloween TV Episodes of All Time
- Meet TIME's Newest Class of Next Generation Leaders
Contact us at letters@time.com